The ATP Sensitive Potassium Channel (KATP) Is a Novel Target for Migraine Drug Development

Migraine is a major global disability, and the ATP-sensitive potassium (K ATP) channel is a promising target for new treatments. Evidence shows that opening the K ATP channel with levcromakalim triggers headaches and migraines in nearly all tested individuals, suggesting its role in migraine pathogenesis. Blocking the K ATP channel, particularly the Kir6.1/SUR2B subtype, could be effective for migraine treatment, as shown in animal models, though human data is lacking. While potential side effects of such blockers may pose challenges, they are expected to be moderate. Future clinical trials are needed to confirm the efficacy and safety of Kir6.1/SUR2B blockers in treating migraines.